322 related articles for article (PubMed ID: 31447838)
1. IL-36β Promotes CD8
Zhao X; Chen X; Shen X; Tang P; Chen C; Zhu Q; Li M; Xia R; Yang X; Feng C; Zhu X; Zhu Y; Sun Z; Zhang X; Lu B; Wang X
Front Immunol; 2019; 10():1803. PubMed ID: 31447838
[TBL] [Abstract][Full Text] [Related]
2. Amino acids and RagD potentiate mTORC1 activation in CD8
Zhang Y; Hu H; Liu W; Yan SM; Li Y; Tan L; Chen Y; Liu J; Peng Z; Yuan Y; Huang W; Yu F; He X; Li B; Zhang H
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883257
[TBL] [Abstract][Full Text] [Related]
3. IL-36γ Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses.
Wang X; Zhao X; Feng C; Weinstein A; Xia R; Wen W; Lv Q; Zuo S; Tang P; Yang X; Chen X; Wang H; Zang S; Stollings L; Denning TL; Jiang J; Fan J; Zhang G; Zhang X; Zhu Y; Storkus W; Lu B
Cancer Cell; 2015 Sep; 28(3):296-306. PubMed ID: 26321222
[TBL] [Abstract][Full Text] [Related]
4. Long Noncoding RNA GM16343 Promotes IL-36β to Regulate Tumor Microenvironment by CD8
Mao D; Hu C; Zhang J; Feng C; Zhang Z; Wang J; Man Z; Zhu Z; Wang Y; Zhao H; Zhu X; Ouyang J; Dong X; Zhao X
Technol Cancer Res Treat; 2019; 18():1533033819883633. PubMed ID: 31684829
[TBL] [Abstract][Full Text] [Related]
5. Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8
Mastelic-Gavillet B; Navarro Rodrigo B; Décombaz L; Wang H; Ercolano G; Ahmed R; Lozano LE; Ianaro A; Derré L; Valerio M; Tawadros T; Jichlinski P; Nguyen-Ngoc T; Speiser DE; Verdeil G; Gestermann N; Dormond O; Kandalaft L; Coukos G; Jandus C; Ménétrier-Caux C; Caux C; Ho PC; Romero P; Harari A; Vigano S
J Immunother Cancer; 2019 Oct; 7(1):257. PubMed ID: 31601268
[TBL] [Abstract][Full Text] [Related]
6. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells.
Gao X; Wang X; Yang Q; Zhao X; Wen W; Li G; Lu J; Qin W; Qi Y; Xie F; Jiang J; Wu C; Zhang X; Chen X; Turnquist H; Zhu Y; Lu B
J Immunol; 2015 Jan; 194(1):438-45. PubMed ID: 25429071
[TBL] [Abstract][Full Text] [Related]
7. Decreased expression of interleukin-36α correlates with poor prognosis in hepatocellular carcinoma.
Pan QZ; Pan K; Zhao JJ; Chen JG; Li JJ; Lv L; Wang DD; Zheng HX; Jiang SS; Zhang XF; Xia JC
Cancer Immunol Immunother; 2013 Nov; 62(11):1675-85. PubMed ID: 24061617
[TBL] [Abstract][Full Text] [Related]
8. Natural killer group 2D and CD28 receptors differentially activate mammalian/mechanistic target of rapamycin to alter murine effector CD8+ T-cell differentiation.
McQueen B; Trace K; Whitman E; Bedsworth T; Barber A
Immunology; 2016 Mar; 147(3):305-20. PubMed ID: 26661515
[TBL] [Abstract][Full Text] [Related]
9. Deletion of MyD88 in T Cells Improves Antitumor Activity in Melanoma.
Bayer AL; Padilla-Rolon D; Smolgovsky S; Hinds PW; Alcaide P
Am J Pathol; 2024 Jun; 194(6):1007-1019. PubMed ID: 38442804
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade.
Ho WS; Wang H; Maggio D; Kovach JS; Zhang Q; Song Q; Marincola FM; Heiss JD; Gilbert MR; Lu R; Zhuang Z
Nat Commun; 2018 May; 9(1):2126. PubMed ID: 29844427
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-36α inhibits colorectal cancer metastasis by enhancing the infiltration and activity of CD8
Wei X; Yao Y; Wang X; Sun J; Zhao W; Qiu L; Zhai W; Qi Y; Gao Y; Wu Y
Int Immunopharmacol; 2021 Nov; 100():108152. PubMed ID: 34555640
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity.
Towne JE; Renshaw BR; Douangpanya J; Lipsky BP; Shen M; Gabel CA; Sims JE
J Biol Chem; 2011 Dec; 286(49):42594-42602. PubMed ID: 21965679
[TBL] [Abstract][Full Text] [Related]
13. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8
Yin W; Song Y; Liu Q; Wu Y; He R
Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970
[TBL] [Abstract][Full Text] [Related]
14. DAPK1 (death associated protein kinase 1) mediates mTORC1 activation and antiviral activities in CD8
Wei Z; Li P; He R; Liu H; Liu N; Xia Y; Bi G; Du Q; Xia M; Pei L; Wang J; Wang G; Tang ZH; Cheng X; Li H; Li Z; Ye L; Laurence A; Lu Y; Yang XP
Cell Mol Immunol; 2021 Jan; 18(1):138-149. PubMed ID: 31541182
[TBL] [Abstract][Full Text] [Related]
15. Tet2 Inactivation Enhances the Antitumor Activity of Tumor-Infiltrating Lymphocytes.
Lee M; Li J; Li J; Fang S; Zhang J; Vo ATT; Han W; Zeng H; Isgandarova S; Martinez-Moczygemba M; Zhou Y; Sun D; Huang Y
Cancer Res; 2021 Apr; 81(8):1965-1976. PubMed ID: 33589517
[TBL] [Abstract][Full Text] [Related]
16. High DGK-α and disabled MAPK pathways cause dysfunction of human tumor-infiltrating CD8+ T cells that is reversible by pharmacologic intervention.
Prinz PU; Mendler AN; Masouris I; Durner L; Oberneder R; Noessner E
J Immunol; 2012 Jun; 188(12):5990-6000. PubMed ID: 22573804
[TBL] [Abstract][Full Text] [Related]
17. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function.
Pellom ST; Dudimah DF; Thounaojam MC; Uzhachenko RV; Singhal A; Richmond A; Shanker A
Oncotarget; 2017 Jan; 8(5):8604-8621. PubMed ID: 28052005
[TBL] [Abstract][Full Text] [Related]
19. Targeting
Le PT; Ha N; Tran NK; Newman AG; Esselen KM; Dalrymple JL; Schmelz EM; Bhandoola A; Xue HH; Singh PB; Thai TH
Front Immunol; 2021; 12():738958. PubMed ID: 34721405
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-36gamma Mediates the
Zhou Y; Chen J; Bai S; Yang F; Yan R; Song Y; Yang B; Li C; Wang J
Viral Immunol; 2024; 37(1):24-35. PubMed ID: 38301135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
